Immuneering Q2 Net Loss Widens to $17.27M; Cash $41.32M
Immuneering Corp reported a widened net loss of $17.27 million for Q2 2026, compared to $14.43 million in Q2 2025, with operating expenses increasing to $19.00 million. The company's cash and cash equivalents significantly decreased to $41.32 million from $128.65 million at the end of 2025, contributing to an accumulated deficit of $311.1 million. Despite the increased losses and cash burn, Immuneering stated that its current cash, cash equivalents, and marketable securities are sufficient to fund operations for at least 12 months.
Key Highlights
- Q2 2026 net loss widened to $17.27 million from $14.43 million YoY.
- Q2 2026 operating expenses increased to $19.00 million from $14.76 million YoY.
- Cash and cash equivalents decreased to $41.32 million from $128.65 million (Dec 31, 2025).
- Accumulated deficit reached $311.1 million as of June 30, 2026.
- Company expects cash, equivalents, and marketable securities to fund operations for at least 12 months.
- Lead candidate atebimetinib is in Phase 1/2a and Phase 3 clinical trials.
Price Impact
More from IMRX
Immuneering Q2 Net Loss $17.3M; Atebimetinib Phase 3 Trial Underway
Immuneering Q2 Net Loss $17.3M; Atebimetinib Phase 3 Underway, Positive ASCO Data
Immuneering's Atebimetinib Shows Broad Antitumor Activity in Preclinical Study